Switzerland · Delayed Price · Currency is CHF Kuros Biosciences AG Earnings Call Transcripts
Fiscal Year 2025
-
Achieved first-time profitability in 2025 with 72% revenue growth and strong operational execution. Guidance for 2026 targets at least 35% revenue growth and 14% adjusted EBITDA margin, with continued expansion in spine, extremities, and trauma segments.
-
Achieved 78% revenue growth and first operating profit in H1 2025, driven by strong execution in spine and extremities, Medtronic partnership, and new product launches. Guidance for at least 60% annual growth is maintained, with minimal tariff impact expected and U.S. production set for H2 2026.
-
Focused on MagnetOs, the company achieved rapid revenue growth, expanded globally, and invested in operational efficiency and clinical evidence. New product launches and entry into extremities and trauma markets support ambitious mid-term sales targets, while strategic partnerships and a robust R&D pipeline drive future growth.
Fiscal Year 2024
-
2024 saw record revenue and EBITDA growth, driven by U.S. and international expansion, a strategic Medtronic partnership, and operational efficiency. Guidance calls for at least 60% revenue growth in 2025, with a strong cash position and no debt supporting further organic and selective inorganic growth.
-
Revenue grew 148% year-over-year in H1 2024, driven by MagnetOs and strong U.S. performance. Adjusted EBITDA margin reached 12.5%, with no debt and robust cash reserves. Outlook remains positive, with continued expansion in both spine and non-spine markets.